ECSP109923A - Bromhidrato de bupropion y aplicaciones terapéuticas - Google Patents

Bromhidrato de bupropion y aplicaciones terapéuticas

Info

Publication number
ECSP109923A
ECSP109923A EC2010009923A ECSP109923A ECSP109923A EC SP109923 A ECSP109923 A EC SP109923A EC 2010009923 A EC2010009923 A EC 2010009923A EC SP109923 A ECSP109923 A EC SP109923A EC SP109923 A ECSP109923 A EC SP109923A
Authority
EC
Ecuador
Prior art keywords
bupropion
bromhydrate
therapeutic applications
treatment
conditions
Prior art date
Application number
EC2010009923A
Other languages
English (en)
Inventor
Robert P Williams
Peter Harris Silverstone
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39225245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP109923(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Publication of ECSP109923A publication Critical patent/ECSP109923A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

Se describen formulaciones de bromhidrato de bupropion, así como también su uso para el tratamiento de afecciones
EC2010009923A 2007-08-07 2010-02-02 Bromhidrato de bupropion y aplicaciones terapéuticas ECSP109923A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/834,848 US7671094B2 (en) 2005-06-27 2007-08-07 Bupropion hydrobromide and therapeutic applications

Publications (1)

Publication Number Publication Date
ECSP109923A true ECSP109923A (es) 2010-03-31

Family

ID=39225245

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009923A ECSP109923A (es) 2007-08-07 2010-02-02 Bromhidrato de bupropion y aplicaciones terapéuticas

Country Status (18)

Country Link
US (2) US7671094B2 (es)
EP (1) EP2185139A2 (es)
JP (1) JP2010535740A (es)
KR (1) KR20100055402A (es)
CN (1) CN101784266B (es)
AU (1) AU2008285660A1 (es)
CA (1) CA2700733A1 (es)
CO (1) CO6251360A2 (es)
CR (1) CR11259A (es)
EC (1) ECSP109923A (es)
HK (1) HK1142811A1 (es)
MX (1) MX2010001449A (es)
NI (1) NI201000015A (es)
NZ (1) NZ582925A (es)
RU (1) RU2485943C2 (es)
SG (1) SG183695A1 (es)
WO (1) WO2009019294A2 (es)
ZA (1) ZA201000425B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535456A (en) * 2002-02-21 2006-08-31 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol for oral administration
US8323692B2 (en) * 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
ZA200711123B (en) 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
WO2007063946A1 (ja) * 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
CA2934988A1 (en) 2008-08-07 2010-02-11 Valeant International Bermuda Bupropion hydrobromide polymorphs
CN101811975B (zh) * 2009-04-20 2013-01-16 浙江普洛医药科技有限公司 氢溴酸安非他酮的多晶型物及其制备方法
TR201001862A1 (tr) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
US11097492B2 (en) * 2015-03-02 2021-08-24 G6 Materials Corp. Thermoplastic composites comprising water-soluble PEO graft polymers useful for 3-dimensional additive manufacturing
EP3675842A4 (en) * 2017-08-31 2021-05-19 Purdue Pharma L.P. PHARMACEUTICAL DOSAGE FORMS
WO2022240819A1 (en) * 2021-05-11 2022-11-17 Rose Research Center, Llc Combination treatment methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038502A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6033686A (en) 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6780871B2 (en) 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US20030044462A1 (en) 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
CN1819821B (zh) * 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
US20070264358A1 (en) * 2004-06-04 2007-11-15 Wittlin William A Methods and Compositions for Treating Mood Disorder
ZA200711123B (en) 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
BRPI0617382A2 (pt) 2005-10-14 2017-07-11 H Lundbeck As Métodos para tratar um distúrbio do sistema nervoso central em um paciente, para tratar um paciente sofrendo de condições e uma disfunção sexual, e para reduzir um retardo na eficácia terapêutica em seguida ao início do tratamento
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2934988A1 (en) 2008-08-07 2010-02-11 Valeant International Bermuda Bupropion hydrobromide polymorphs

Also Published As

Publication number Publication date
WO2009019294A3 (en) 2009-08-13
HK1142811A1 (en) 2010-12-17
CN101784266A (zh) 2010-07-21
US20100104639A1 (en) 2010-04-29
SG183695A1 (en) 2012-09-27
ZA201000425B (en) 2011-04-28
AU2008285660A1 (en) 2009-02-12
MX2010001449A (es) 2010-03-10
WO2009019294A2 (en) 2009-02-12
WO2009019294A9 (en) 2009-06-11
EP2185139A2 (en) 2010-05-19
NZ582925A (en) 2012-09-28
KR20100055402A (ko) 2010-05-26
CO6251360A2 (es) 2011-02-21
US7671094B2 (en) 2010-03-02
JP2010535740A (ja) 2010-11-25
CN101784266B (zh) 2012-07-18
US20080075774A1 (en) 2008-03-27
RU2010107843A (ru) 2011-09-20
RU2485943C2 (ru) 2013-06-27
CA2700733A1 (en) 2009-02-12
NI201000015A (es) 2011-03-23
US8354453B2 (en) 2013-01-15
CR11259A (es) 2010-08-05

Similar Documents

Publication Publication Date Title
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
CL2011000301A1 (es) Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
UY32918A (es) Nuevos compuestos de 2-piridona
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
UY32659A (es) Pirazinilpirazoles
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
PA8784301A1 (es) Oxazolidinonas sustituidas y su uso
HN2010000128A (es) Imidazoles sustituidos con heterociclilamida